The Lynx Group, a global strategic alliance of medical communications and education companies, is pleased to announce that its Journal of Hematology Oncology Pharmacy™ (JHOP) has been named the official publication of the Hematology/Oncology Pharmacy Association (HOPA).
CRANBURY, N.J. (PRWEB) March 16, 2020 -- The Lynx Group, a global strategic alliance of medical communications and education companies, is pleased to announce that its Journal of Hematology Oncology Pharmacy™ (JHOP) has been named the official publication of the Hematology/Oncology Pharmacy Association (HOPA). As part of this agreement, JHOP will serve as a platform through which HOPA members can disseminate original findings, exchange best practices and find support for its growing community.
“It’s an honor to know that HOPA and its members find value in JHOP,” says Russell Hennessy, Executive Vice President, the Lynx Group. “We are excited to partner with HOPA in this capacity and to continuing to provide JHOP subscribers with access to consistently high-quality content.”
David DeRemer, HOPA 2020/21 president says, “HOPA is looking forward to our alliance with the Lynx Group and being able to provide the hematology/ oncology pharmacy community with a most-valued resource like JHOP.”
Since its founding in 2011, JHOP has provided hematology and oncology pharmacists with peer-reviewed information relevant to hematologic and oncologic conditions. Content, which is written by and for industry professionals, aims to help the publication’s 5,000 subscribers optimize drug therapy for patients. JHOP is published six times a year.
About Amplity Health
Amplity Health proudly serves as co-founder and association management company of the Academy of Oncology Nurse & Patient Navigators (AONN+) and the Association for Value-Based Cancer Care (AVBCC).
The true partner of global healthcare companies, Amplity Health continually challenges the boundaries of medical and commercial strategies to accelerate the approval and launch of new drugs to improve the lives of patients. We are proud of our inclusive culture and our EPIIC values. Amplity has the expertise, global infrastructure, and data-driven insights to help clients overcome their medical and commercial challenges.
Amplity’s wide-ranging capabilities include clinical and medical outsourced teams; clinical and medical capability development; companion diagnostic and precision medicine solutions; medical communications; expert engagement; remote and field solutions for patients, payers, and physicians; and strategic and access consulting. Amplity’s one-of-a-kind Insights database offers clients a detailed view into patient–provider interactions and provider treatment rationale not found through any other provider.
For more information, visit amplity.com. Connect with Amplity on Twitter and LinkedIn.
Amplity Health is a portfolio company of Altamont Capital Partners.
About the Hematology/Oncology Pharmacy Association (hoparx.org) Hematology/Oncology Pharmacy Association (HOPA) is a nonprofit, education-based organization formed in 2004 to help oncology and hematology pharmacy practitioners and their associates the best possible cancer care. HOPA supports research, provides education, encourages professional development and advocates for health policy issues that improve patient care. HOPA serves more than 2,700 members in the fields of oncology pharmacy, pharmacy administration, and research, and includes pharmacy residents, interns, and technicians specializing in hematology/oncology practice.